Tango Therapeutics, Inc. Overview
Pro stress-test →Tango Therapeutics is a clinical-stage precision oncology company focused on discovering novel drug targets for cancer treatment using synthetic lethality principles. The company develops genetically targeted therapies aimed at specific patient populations with unmet medical needs.
Strategic Profile
Pro stress-test →Tango leverages synthetic lethality and novel genetics-based approaches to develop medicines that take direct aim at specific tumors, including expanding into tumor suppressor gene loss and immune evasion mechanisms. The company's pipeline includes PRMT5 inhibitors for both CNS and non-CNS cancers, plus CoREST platform programs.
Competitive Landscape
Pro stress-test →Tango competes in the precision oncology space with companies including Prelude Therapeutics, Repare Therapeutics, IDEAYA Biosciences, and FoRx Therapeutics. The competitive advantage lies in the synthetic lethality platform and patient-centric approach to genetically defined tumors.
Industry Context
Tango Therapeutics, Inc. operates in Biotechnology - Precision Oncology.
Key facts
Founded: 2017 · Headquarters: Boston, Massachusetts · Revenue: $66.5M · Market cap: $1.41B